The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 3 June 2004, www.theannals.com, DOI 10.1345/aph.1E004.
 The Annals of Pharmacotherapy: Vol. 38, No. 7, pp. 1194-1196. DOI 10.1345/aph.1E004
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Magnet, M. K
Right arrow Articles by Kapfhammer, H.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magnet, M. K
Right arrow Articles by Kapfhammer, H.-P.

Amantadine in the Akinetic-Rigid Variant of Huntington's Disease

Markus K Magnet, MD

University Clinic of Psychiatry, Karl-Franzens University Graz, Graz, Austria

Raphael M Bonelli, MD

Staff Scientist, University Clinic of Psychiatry, Karl-Franzens University Graz

Hans-Peter Kapfhammer, MD PhD

Professor, Head of the Department, University Clinic of Psychiatry, Karl-Franzens University Graz

Reprints: Raphael M Bonelli MD, University Clinic of Psychiatry, Karl-Franzens University Graz, Auenbruggerplatz 31, 8036 Graz, Austria, fax 43 316 385 3556, raphael.bonelli{at}klinikum-graz.at

OBJECTIVE: To report the effects of amantadine on an akinetic-rigid variant of Huntington's disease (HD).

CASE SUMMARY: We describe a 36-year-old woman with HD who was treated with intravenous amantadine for 5 days. The woman was evaluated with the Unified Huntington's Disease Rating Scale before and after treatment. Parkinsonism, bradykinesia, and dystonia improved significantly.

DISCUSSION: Amantadine is a noncompetitive N-methyl D-aspartate receptor antagonist. It is mainly used in the treatment of Parkinson's disease, as it increases dopamine levels in the brain. This effect is said to ameliorate akinesia. Although the effect of amantadine on choreatic dystonia in HD has been reported in several studies, to the best of our knowledge, this is the first report of the ameliorative effects of amantadine on the rigid form of HD. Our patient showed improvements of gait, parkinsonism, and dystonia. Fine-motor tasks and eye movement did not change significantly.

CONCLUSIONS: We suggest that amantadine treatment might be of value to patients with the akinetic-rigid variant of HD.

Key Words: amantadine, Huntington's disease, akinetic-rigid variant

Published Online, June 3, 2004. www.theannals.com, DOI 10.1345/aph.1E004


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
E. Z Schmidt, P. Hofmann, H.-P. Kapfhammer, and R. M Bonelli
Drug holiday in Huntington's disease
Ann. Pharmacother., April 1, 2005; 39(4): 773 - 773.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.